Scott B. Seibel

648 total citations
15 papers, 326 citations indexed

About

Scott B. Seibel is a scholar working on Pharmacology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Scott B. Seibel has authored 15 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmacology, 6 papers in Molecular Biology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Scott B. Seibel's work include Mast cells and histamine (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Inflammatory mediators and NSAID effects (3 papers). Scott B. Seibel is often cited by papers focused on Mast cells and histamine (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Inflammatory mediators and NSAID effects (3 papers). Scott B. Seibel collaborates with scholars based in United States and Germany. Scott B. Seibel's co-authors include A.P. Ricketts, Kristin M. Lundy, Shigeru Hayashi, Annette M. Silvia, Richard Gedrich, Theresa LaVallee, Diego Alvarado, Lawrence J. Thomas, Diane Young and J. Goldstein and has published in prestigious journals such as PLoS ONE, Cancer Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Scott B. Seibel

15 papers receiving 317 citations

Peers

Countries citing papers authored by Scott B. Seibel

Since Specialization

Citations

This map shows the geographic impact of Scott B. Seibel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott B. Seibel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott B. Seibel more than expected).

Fields of papers citing papers by Scott B. Seibel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott B. Seibel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott B. Seibel. The network helps show where Scott B. Seibel may publish in the future.

Co-authorship network of co-authors of Scott B. Seibel

This figure shows the co-authorship network connecting the top 25 collaborators of Scott B. Seibel. A scholar is included among the top collaborators of Scott B. Seibel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott B. Seibel. Scott B. Seibel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study 2022 ·Allergy ·Diego Alvarado, Marcus Maurer, Richard Gedrich, Scott B. Seibel, Michael Murphy, (unknown), J. Goldstein, Andrea Crocker, Laura Vitale, (unknown), Lawrence J. Thomas, Thomas Hawthorne, Tibor Keler, Diane Young, Elizabeth Crowley, Martin Kankam, Margo Heath‐Chiozzi	62
2	D100 CDX-0159, AN ANTI-KIT MONOCLONAL ANTIBODY, AS A MODULATOR OF MAST CELL-RELATED DISEASES 2019 ·Annals of Allergy Asthma & Immunology ·Scott B. Seibel, Laura Vitale, (unknown), J. Goldstein, (unknown), Andrea Crocker, (unknown), Christopher J. Patterson, (unknown), Russell A. Hammond, Tibor Keler, Richard Gedrich	1
3	Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression 2017 ·Molecular Cancer Therapeutics ·Andrew J. Garton, Scott B. Seibel, Lori Lopresti‐Morrow, (unknown), (unknown), Sreekala Mandiyan, E. Sergio Trombetta, (unknown), Theresa LaVallee, Richard Gedrich	27
4	ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC 2017 ·PLoS ONE ·Diego Alvarado, Gwenda F. Ligon, Jay S. Lillquist, Scott B. Seibel, Gerald Wallweber, Veronique Neumeister, David L. Rimm, Gerald McMahon, Theresa LaVallee	18
5	Abstract 1196: Combination of neuregulin with EGFR activation signatures predict activity of the anti-ErbB3 antibody KTN3379 in SCCHN 2016 ·Cancer Research ·Gwenda F. Ligon, Jay S. Lillquist, Scott B. Seibel, (unknown), Veronique Neumeister, David L. Rimm, Theresa LaVallee, Diego Alvarado	2
6	Targeting KIT on innate immune cells enhances the antitumor activity of checkpoint inhibitors in vivo 2015 ·Journal for ImmunoTherapy of Cancer ·Richard Gedrich, Scott B. Seibel, Theresa LaVallee, Joseph P. Eder	2
7	Abstract 1558: Association of ErbB/HER biomarkers with antitumor activity of the anti-ErbB3/HER3 monoclonal antibody KTN3379 in SCCHN 2015 ·Cancer Research ·Diego Alvarado, (unknown), Scott B. Seibel, Ahmed Chenna, (unknown), Weidong Huang, (unknown), (unknown), Theresa LaVallee	1
8	Comparative structure–activity relationship studies of 1-(5-methylsulfonylpyrid-2-yl)-5-alkyl and (hetero)aryl triazoles and pyrazoles in canine COX inhibition 2007 ·Bioorganic & Medicinal Chemistry Letters ·Subas M. Sakya, Andrei Shavnya, Hengmiao Cheng, Chao Li, (unknown), Jin Li, (unknown), Burton H. Jaynes, Donald W. Mann, (unknown), Scott B. Seibel, Michelle L. Haven, Michael P. Lynch	10
9	5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: Molecular modeling studies on binding contribution of 1-(5-methylsulfonyl)pyrid-2-yl and 4-nitrile 2006 ·Bioorganic & Medicinal Chemistry Letters ·Subas M. Sakya, Xinjun Hou, Martha L. Minich, (unknown), Andrei Shavnya, (unknown), Hengmiao Cheng, Jin Li, Burton H. Jaynes, Donald W. Mann, (unknown), Scott B. Seibel, Michelle L. Haven	28
10	Pharmacokinetics and pharmacodynamics of azithromycin in gerbils with haemophilus influenzae middle ear infection 2005 ·Clinical Pharmacology & Therapeutics ·Ólanrewaju O. Okusanya, Alan Forrest, Brent M. Booker, Sujata M. Bhavnani, D Girard, Steven M. Finegan, Judith C. Hamel, Scott B. Seibel, Lisa J. Benincosa, A. Sharma	1
11	In Vitro Microbiological Characterization of Novel Macrolide CP-163,505 for Animal Health Specific Use. 1998 ·The Journal of Antibiotics ·(unknown), Scott B. Seibel, Barbara J. Kamicker, (unknown), (unknown), Scott J. Hecker, Jay Bergeron, James A. Retsema, Shigeru Hayashi	7
12	Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs 1998 ·American Journal of Veterinary Research ·A.P. Ricketts, Kristin M. Lundy, Scott B. Seibel	121
13	Dust in the wind, experimental casting of bronze in sand moulds 1998 ·Barbara S. Ottaway, Scott B. Seibel	6
14	Structure-activity Relationships of Hygromycin A and Its Analogs: Protein Synthesis Inhibition Activity in a Cell Free System. 1997 ·The Journal of Antibiotics ·Shigeru Hayashi, (unknown), Scott B. Seibel, Annette M. Silvia	31
15	Cyclic homopentapeptides 2. Synthetic modifications of viomycin 1997 ·Bioorganic & Medicinal Chemistry Letters ·Joe Lyssikatos, (unknown), J. P. Clancy, John P. Dirlam, Steven M. Finegan, Agnès Girard, Shigeru Hayashi, Daniel P. Larson, (unknown), (unknown), (unknown), J.W. Petitpas, Scott B. Seibel, Chi B. Vu	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact